Application of cystatin C reduction ratio to high-flux hemodialysis as an alternative indicator of the clearance of middle molecules

Korean Journal of Internal Medicine

Volumn 25, Issue 1, 2010, Pages 77-81

  Park, Joon Sung ^a   Kim, Gheun Ho ^a   Kang, Chong Myung ^a   Lee, Chang Hwa ^a  

^a Hanyang University College of Medicine   (South Korea)

Author keywords

Beta 2 microglobulin; Cystatin C; Dialysis

Indexed keywords

BETA 2 MICROGLOBULIN; CYSTATIN C; UREA;

ADULT; ARTICLE; BLOOD LEVEL; CLEARANCE; CLINICAL TRIAL; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PARTICLE ENHANCED IMMUNONEPHELOMETRY;

ADULT; AGED; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYSTATIN C; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEPHELOMETRY AND TURBIDIMETRY; RENAL DIALYSIS; UREA; UREMIA;

EID: 77949370625     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2010.25.1.77     Document Type: Article

References (32)

1. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
2. Prado M, Roa LM, Palma A, Milan JA. Double target comparison of blood-side methods for measuring the hemodialysis dose. Kidney Int 2005;68:2863-2876.
3. Vienken J, Bowry S. Quo vadis dialysis membrane? Artif Organs 2002;26:152-159.
4. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004;41:467-550.
5. Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int 2006;69:399-405.
6. Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 2006;15:270-275.
7. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-1421.
8. Mojiminiyi OA, Abdella N. Evaluation of cystatin C and beta-2 microglobulin as markers of renal function in patients with type 2 diabetes mellitus. J Diabetes Complications 2003;17:160-168.
9. Campo A, Lanfranco G, Gramaglia L, Goia F, Cottino R, Giusto V. Could plasma cystatin C be useful as a marker of hemodialysis low molecular weight proteins removal? Nephron Clin Pract 2004;98:c79-c82.
10. Thysell H, Grubb A, Lindholm T, Ljunggren L, Martensson L. Cystain C: a new marker of biocompatibility or a good marker for the redistribution of LMW proteins during hemodialysis? ASAIO Trans 1988;34:202-204.
11. Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006;48 Suppl 1:S2-S90.
12. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993;4:1205-1213.
13. Diaz-Buxo JA, Loredo JP. Standard Kt/V: comparison of calculation methods. Artif Organs 2006;30:178-185.
14. Cheung AK, Levin NW, Greene T, et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003;14:3251-3263.
15. Ayli D, Ayli M, Azak A, et al. The effect of high-flux hemodialysis on renal anemia. J Nephrol 2004;17:701-706.
16. Vanholder R, Glorieux G, De Smet R, Lameire N. New insights in uremic toxins. Kidney Int Suppl 2003;(84):S6-S10.
17. Basile C. The effect of convection on the nutritional status of haemodialysis patients. Nephrol Dial Transplant 2003;18 Suppl 7:vii46-vii49.
18. Leypoldt JK, Cheung AK. Removal of high-molecular-weight solutes during high-efficiency and high-flux haemodialysis. Nephrol Dial Transplant 1996;11:329-335.
19. Clark WR, Gao D. Determinants of uraemic toxin removal. Nephrol Dial Transplant 2002;17 Suppl 3:30-34.
20. Locatelli F, Manzoni C, Di Filippo S. The importance of convective transport. Kidney Int Suppl 2002;(80):115-120.
21. Lindsay RM, Henderson LW. Adequacy of dialysis. Kidney Int Suppl 1988;24:S92-S99.
22. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006;70:794-799.
23. Ayli M, Ayli D, Azak A, et al. The effect of high-flux hemodialysis on dialysis-associated amyloidosis. Ren Fail 2005;27:31-34.
24. Locatelli F, Andrulli S, Pecchini F, et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant 2000;15:1399-1409.
25. Leypoldt JK, Cheung AK, Deeter RB. Rebound kinetics of beta2-microglobulin after hemodialysis. Kidney Int 1999;56:1571-1577.
26. Ward RA, Greene T, Hartmann B, Samtleben W. Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int 2006;69: 1431-1437.
27. Newman DJ. Cystatin C. Ann Clin Biochem 2002;39(Pt 2):89-104.
28. Levy E, Jaskolski M, Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol 2006;16:60-70.
29. Reed CH. Diagnostic applications of cystatin C. Br J Biomed Sci 2000;57:323-329.
30. Revesz T, Ghiso J, Lashley T, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003;62:885-898.
31. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007;115:173-179.
32. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145:237-246.